These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 25212833)

  • 21. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
    Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
    Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells.
    Umeh-Garcia M; Simion C; Ho PY; Batra N; Berg AL; Carraway KL; Yu A; Sweeney C
    Cancer Res; 2020 Feb; 80(3):418-429. PubMed ID: 31694904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
    Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
    Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
    D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
    Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
    Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
    Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer.
    Huang SP; Liu PY; Kuo CJ; Chen CL; Lee WJ; Tsai YH; Lin YF
    J Hematol Oncol; 2017 Jun; 10(1):114. PubMed ID: 28576130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NOTCH4 is a potential therapeutic target for triple-negative breast cancer.
    Nagamatsu I; Onishi H; Matsushita S; Kubo M; Kai M; Imaizumi A; Nakano K; Hattori M; Oda Y; Tanaka M; Katano M
    Anticancer Res; 2014 Jan; 34(1):69-80. PubMed ID: 24403446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
    Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
    Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
    Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
    Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
    Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
    Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
    Kim S; Lee J; Jeon M; Lee JE; Nam SJ
    Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
    Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological and clinical significance of flap endonuclease‑1 in triple‑negative breast cancer: Support of metastasis and a poor prognosis.
    Xu L; Qu JL; Song N; Zhang LY; Zeng X; Che XF; Hou KZ; Shi S; Feng ZY; Qu XJ; Liu YP; Teng YE
    Oncol Rep; 2020 Dec; 44(6):2443-2454. PubMed ID: 33125141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
    Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
    Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
    Wu X; Zahari MS; Renuse S; Kelkar DS; Barbhuiya MA; Rojas PL; Stearns V; Gabrielson E; Malla P; Sukumar S; Mahajan NP; Pandey A
    Oncotarget; 2017 Jan; 8(2):2971-2983. PubMed ID: 27902967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer.
    Wu J; Liu P; Tang H; Shuang Z; Qiu Q; Zhang L; Song C; Liu L; Xie X; Xiao X
    Curr Cancer Drug Targets; 2018; 18(4):382-389. PubMed ID: 29484998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.